Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 176

1.
3.

Becaplermin gel in the treatment of pressure ulcers: a phase II randomized, double-blind, placebo-controlled study.

Rees RS, Robson MC, Smiell JM, Perry BH.

Wound Repair Regen. 1999 May-Jun;7(3):141-7.

4.

Clinical efficacy of becaplermin (rhPDGF-BB) gel. Becaplermin Gel Studies Group.

Wieman TJ.

Am J Surg. 1998 Aug;176(2A Suppl):74S-79S.

PMID:
9777976
5.

Recombinant human platelet-derived growth factor-BB (becaplermin) for healing chronic lower extremity diabetic ulcers: an open-label clinical evaluation of efficacy.

Embil JM, Papp K, Sibbald G, Tousignant J, Smiell JM, Wong B, Lau CY.

Wound Repair Regen. 2000 May-Jun;8(3):162-8.

PMID:
10886806
6.

Treatment of chronic ulcers in the lower extremities with topical becaplermin gel .01%: a multicenter open-label study.

Guzman-Gardearzabal E, Leyva-Bohorquez G, Salas-Colín S, Paz-Janeiro JL, Alvarado-Ruiz R, García-Salazar R.

Adv Ther. 2000 Jul-Aug;17(4):184-9.

PMID:
11185057
7.

Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity ulcers.

Steed DL.

Plast Reconstr Surg. 2006 Jun;117(7 Suppl):143S-149S; discussion 150S-151S. Review.

PMID:
16799381
9.

Clinical safety of becaplermin (rhPDGF-BB) gel. Becaplermin Studies Group.

Smiell JM.

Am J Surg. 1998 Aug;176(2A Suppl):68S-73S.

PMID:
9777975
10.
11.

Becaplermin.

Balfour JA, Noble S.

BioDrugs. 1999 May;11(5):359-64.

PMID:
18031145
12.

Efficacy of topical recombinant human platelet-derived growth factor for treatment of diabetic lower-extremity ulcers: Systematic review and meta-analysis.

Zhao XH, Gu HF, Xu ZR, Zhang Q, Lv XY, Zheng XJ, Yang YM.

Metabolism. 2014 Oct;63(10):1304-13. doi: 10.1016/j.metabol.2014.06.005. Epub 2014 Jun 13. Review.

13.

Growth factors for treating diabetic foot ulcers.

Martí-Carvajal AJ, Gluud C, Nicola S, Simancas-Racines D, Reveiz L, Oliva P, Cedeño-Taborda J.

Cochrane Database Syst Rev. 2015 Oct 28;(10):CD008548. doi: 10.1002/14651858.CD008548.pub2. Review.

PMID:
26509249
15.

Cost-effectiveness of becaplermin for nonhealing neuropathic diabetic foot ulcers.

Sibbald RG, Torrance G, Hux M, Attard C, Milkovich N.

Ostomy Wound Manage. 2003 Nov;49(11):76-84.

16.

Cost effectiveness of Becaplermin in the treatment of diabetic foot ulcers in four European countries.

Ghatnekar O, Persson U, Willis M, Odegaard K.

Pharmacoeconomics. 2001;19(7):767-78.

PMID:
11548912
17.

Topical treatment of hypertensive leg ulcers with platelet-derived growth factor-BB: a randomized controlled trial.

Senet P, Vicaut E, Beneton N, Debure C, Lok C, Chosidow O.

Arch Dermatol. 2011 Aug;147(8):926-30. doi: 10.1001/archdermatol.2011.84. Epub 2011 Apr 11.

PMID:
21482863
18.

[Becaplermin gel (Regranex gel)].

Senet P.

Ann Dermatol Venereol. 2004 Apr;131(4):351-8. Review. French.

PMID:
15258509
19.

Treatment of stingray injury with topical becaplermin gel.

Baldinger PJ.

J Am Podiatr Med Assoc. 1999 Oct;89(10):531-3.

PMID:
10546426
20.

Supplemental Content

Support Center